Brief: Insilico Medicine Cayman TopCo Says Co & SK Biopharmaceuticals Enter AI-Powered RD Collab Worth Up To $2.5 Bln
22/06/2026 05:34
BRIEF-Insilico Medicine Cayman TopCo Says Co & SK Biopharmaceuticals Enter AI-Powered RD Collab Worth Up To $2.5 Bln June 22 (Reuters) - Insilico Medicine Cayman TopCo 3696.HK:
AND SK BIOPHARMACEUTICALS ENTER AI-POWERED RD COLLABORATION WORTH UP TO $2.5 BILLION
TO RECEIVE UP TO $18 MILLION IN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS
TOTAL POTENTIAL DEAL VALUE EXCEEDS $2.5 BILLION INCLUDING MILESTONES AND ROYALTIES
Further company coverage: 3696.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SK Biopharmaceuticals
See all newsBrief: Sk Biopharmaceuticals Co Signs Licensing-In Contract With 1St Biotherapeutics
US FDA pauses new enrollment in Biohaven's epilepsy drug trials (updated)
US FDA pauses new enrollment in Biohaven's epilepsy drug trials
Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million
U.S. STOCKS ON THE MOVE-Meta, Kohl's, J.M. Smucker